---
title: "Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260697344.md"
description: "Aidea Pharma announced on October 11th that the results of its self-developed anti-HIV drug Fubangde® SPRINT's Phase III clinical study have been published in BMC Medicine. This journal is a top medical journal with an impact factor of 9.4, and the influence of the published research results surpasses that of imported similar products"
datetime: "2025-10-11T00:13:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260697344.md)
  - [en](https://longbridge.com/en/news/260697344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260697344.md)
generator: "portal-rs"
---

# Aidea Pharma: The full text of the 96-week study on Fubangde® SPRINT was published in BMC Medicine

On October 11th, Aidea Pharma announced that the company's independently developed China's first "three-in-one" single-tablet combination innovative drug, the next-generation non-nucleoside combination formulation AINOMITE, has had its key Phase III clinical research results published in full in the flagship medical journal BMC Medicine, under the global academic publishing giant Springer Nature. This journal is a top-tier journal in the JCR and the Chinese Academy of Sciences' Zone 1, with a 5-year impact factor of 9.4. In addition, the influence of this publication has currently surpassed that of imported similar products

### Related Stocks

- [688488.CN](https://longbridge.com/en/quote/688488.CN.md)

## Related News & Research

- [Why are bond yields surging, and why does it matter?](https://longbridge.com/en/news/296320283.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [REG - Gooch & Housego PLC Odyssean Inv. Trust - Holding(s) in Company](https://longbridge.com/en/news/296616769.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**